Summary It has been recognized that the tumour markers alpha-fetoprotein (AFP) and human chononic gonadotrophin (HCG) may show a transient elevation after the initiation of chemotherapy in non-seminomatous testicular cancer. We investigated the prognostic importance of these so-called marker surges in a cohort of patients treated with cisplatin combination chemotherapy between 1983 and 1991. A total of 669 patients were studied. Of 352 patients who had an elevated AFP at the start of treatment and for whom we had data at both day 1 and day 8. 101 (29%) had a surge. Of 317 patients for whom we had data for HCG. 80 patients (25%) had a surge. It was found that an AFP surge was a strong adverse prognostic factor for progression [hazard ratio (HR) 2.28. P = 0.005]. There was no statistically significant difference in survival (HR 1.65. P = 0.13). There was no prognostic significance of a HCG surge, either for progression or for survival. To investigate whether a surge was an independent prognostic factor for progression and survival, multivariate Cox regression models were fitted using the independent prognostic factors for progression and survival and the surge/decline variable. An AFP surge was retained in the final model for progression. A HCG surge was of no prognostic importance for progression or survival. We conclude that an AFP surge has an adverse prognostic significance. independent of pretreatment characteristics.
disease-free survival in patients with disseminated testicular nonseminoma (Levi et al. 1988 : Peckham et al. 1988 : Roth et al. 1988 : Stoter et al. 1989 . Patients w-ho fail treatment are usually characterized bv a hiah tumour load and/or high serum concentrations of the tumour markers alpha-fetoprotein (AFP) and human chorionic 5onadotrophin (HCG). Multixaniate prognostic factor anal-ses have led to the dex-elopment of models which can be used to classify patients as hax ing a good. intermediate or poor prognosis on the basis of criteria at the start of treatment (Bosl et al. 1983: Medical Research Council Workinc Partx on Testicular Tumours.
1985 : Birch et al. 1986 : Stoter et al. 1987 : Droz et al. 1988 : Hitchins et al. 1989 : Stoter and S-lx ester. 1990 : Aass et al. 1991 : Mead et al. 1992 : International Germ Cell Cancer CollaboratiVe Group. 1997 ). In addition. it wxould be useful to have a method for early prediction of an adx erse treatment outcome after the start of chemotherapy.
The most common pattern of marker response after the initiation of chemotherapy is an exponential regression to normal levels. How ever. it has been recognized for many y-ears that tumour markers mav showx a transient elevation durinn the first (Vogelzang et al. 1982: Horx-ich and Peckham. 19861 . These so-called marker surges are beliexed to result from the release of HCG and/or AFP from l-tic tumour cells and miaht reflect a hiah sensitivitv of the tumour cells to the chemotherapy.
In the initial reports in small series of patients. no prognostic significance of a surge w as established. To date. neither the precise incidence of marker surges nor its possible implications have been reported. In the current study. w-e inx estigated the prognostic importance of marker surges in a total of 669 patients treated w-ith cisplatin combination chemotherapy for metastatic non-seminomatous testicular cancer betw een 1983 and 1991.
PATIENTS AND METHODS Patients
The 669 patients in this study w ere treated in the framew ork of tw-o simultaneous randomized trials of the European Organization for
Research and Treatment of Cancer (EORTC) (Wit de et al. 1995 (Wit de et al. . 1997 ). In the first study. 250 patients with lmph node metastases > 5 cm and/or lung metastases > 2 cm and/or HCG > 10 000 IU F' and/or AFP > 1000 /IL-1 xwere treated with cisplatin. etoposide and bleom-cin (BEP) or an alternating regimen of BEP and cisplatin. vinblastine. and bleomycin (PVB). In the other study. 419 patients wxho had smaller metastases and low-er marker lexels than specified aboxve were treated w ith BEP or EP In both protocols. induction chemotherapy consisted of four treatment cycles for a total duration of 12 w eeks. After four c%-cles of 1350 Serum marker values and definitions
In determining whether a surge occurred, the first value that was used was the value on the day at the start of chemotherapy, day 1. The second sample was the first value obtained during the administration of the first cycle of chemotherapy, which was usually around day 8 at the time of the second administration of bleomycin. A surge was defined as any increase in marker levels (value day 8 > day 1). A decline was defined as a greater than 10% decrease. Patients with less than or equal to 10% decreases were excluded from the analysis because it is unclear whether such values truly represent a decline, or whether a surge may have occurred one or several days before this second measurement point.
Statistical methods
Progression-free rates and survival rates were estimated using the Kaplan-Meier technique (Kaplan and Meier, 1958) . Univariate and multivariate analyses of the time to progression and of the duration of survival were performed using Cox proportional hazards regression models (Cox, 1972) . A 0.05 significance level was used in all analyses. All variables which were significant in the univariate analysis were entered in the first step of the multivariate model. A step-down procedure was then applied to determine those factors of most prognostic importance. The effect of a variable is described using the hazard ratio (HR) together with its 95% confidence interval (CI). The logistic regression model (Cox and Snell, 1989 ) was used to determine whether there was an association between the patients' initial characteristics and the occurrence of a surge. Figure 1 ). There was no statisticallv significant difference in survival (HR 1.65: CI 0.86-3.18: P = 0.13: Figure 2 ). As can be seen in Figure 2 . the curves suggest a possible effect. but the number of deaths is low.
RESULTS

Number of patients
thus. the power for detecting an effect is also low. Univariate and multivariate analysis of the pretreatment characteristics as prognostic factors for progression and survival
Both univariate and multivariate evaluations of the pretreatment characteristics as possible prognostic factors for progression and survival were carried out. Univariately, both for progression and for survival, the initial marker values, the presence and size of nodal disease, the presence and size of pulmonary metastases, and the presence of non-pulmonary visceral metastases were confirmed to be significant parameters (data not shown). The prognostic factors that were retained in the final multivariate models for progression and survival are shown in 2-Surge>30% Figure 4 Progression according to the percentage change in AFP pretreatment factors as variables. In the analysis of time to progression, AFP surge was retained in the final model ( Table 3 ), indicating that AFP surge adds prognostic information to that contained in the pretreatment prognostic factors. In the analysis using survival as the end point, AFP surge was not retained in the final model (Table 3) . As expected from the univariate analysis, HCG surge did not appear to be a prognostic factor for either progression or survival (data not shown).
In addition, multivariate models were fitted using only the surge/decline variable and the risk group according to the IGCCCG classification. For this purpose, the classification good/intermediate versus poor prognosis was used because in our data set the difference in time to progression and survival between the poor prognosis group and the good/intermediate prognosis group was much larger than the difference between the good prognosis and the intermediate prognosis group (30% vs 10%) .
In the analysis for progression, it was again found that AFP surge is a significant predictor for progression, independent of the IGCCCG classification (HR 1.41; CI 1.08-1.85; P = 0.013), thus, adding to the strong predictive power of the IGCCCG classification (Table 4 ). An AFP surge did not add to the prediction of survival, once the risk group was known. Figure 3 shows the effect of an AFP surge in the patients of the good/intermediate prognosis category: patients with a surge appear to have an 8% worse treatment outcome than those whose markers decline from day 1 onwards [HR 1.98 (surge/decline); CI 0.94-4.16; P = 0.07]. The fact that this P-value is only of borderline significance should be related to the small number of events in this subgroup.
Extent of AFP surge as a prognostic factor for time to progression Finally, the potential effect of the percentage change in AFP values (decline vs < 30% surge vs > 30% surge) on the time to progression was investigated both in a univariate and in a multivariate model taking the IGCCCG classification into account (Figure 4) . The data suggest that the prognosis of the patients worsens according to the extent of the surge, a larger percentage surge being associated with a worse prognosis. The hazard ratio for the extent of the surge was 1.68 (CI 1.24-2.29; P = 0.001) in the 1354 R de Wit et al univariate analysis indicating a worsening of the prognosis by a factor of 1.68 for patients with a < 30%7-surge compared with those with a decline. or for those with a > 30% surge compared w-ith those w-ith a smaller surgye (Figure 5 showing an AFP surge.
We conclude that an AFP surge has an adverse prognostic significance. that is independent of the pretreatment prognostic characteristics. An AFP surre adds to the prognostic importance of the current risk classification of the IGCCCG.
